MTOR and renal carcinoma: Thus, we first tested a variety of doses of the mTOR inhibitor (100 nM to 10 μM of TEMS) in 769-P, 786-O, A-498 malignant renal cancer cells as well as the normal immortalized HK-2 cell line.